NASDAQ:VIVE • US92852W5013
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for VIVEVE MEDICAL INC (VIVE).
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | ||
|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 6.57M -64.52% | 5.48M -16.59% | 6.426M 17.26% | 7.028M 9.37% | 11.363M 61.68% | 22.328M 96.50% | |
| EBITDA YoY % growth | -28.75M 34.93% | -17.2M 40.17% | -20.43M -18.78% | N/A | N/A | N/A | |
| EBIT YoY % growth | -29.93M 33.44% | -18.5M 38.19% | -21.553M -16.50% | -20.93M 2.89% | -20.533M 1.90% | -14.321M 30.25% | |
| Operating Margin | -455.56% | -337.59% | -335.40% | -297.81% | -180.70% | -64.14% | |
| EPS YoY % growth | -608.87 62.65% | -17.05 97.20% | -2.81 83.52% | -2.60 7.44% | -1.63 37.25% | -0.99 39.38% |
All data in USD
| Q4 / 22 | Q1 / 23 | Q2 / 23 | Q3 / 23 | Q4 / 23 | Q1 / 24 | Q2 / 24 | Q3 / 24 | Q4 / 24 | |
|---|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.63 12.17% | -0.48 28.45% | -0.43 36.06% | -0.38 36.03% | -0.35 45.16% | -0.28 42.55% | -0.26 40.48% | -0.22 40.54% | -0.23 32.35% |
| Revenue Q2Q % growth | 1.805M 5.80% | 2.173M 32.42% | 2.56M 42.62% | 3.009M 78.68% | 3.621M 100.61% | 4.457M 105.11% | 5.131M 100.43% | 5.865M 94.92% | 6.875M 89.86% |
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -5.467M 8.68% | -5.753M -5.11% | -5.294M -5.45% | -4.702M -0.86% | -4.794M 12.31% | -4.192M 27.13% | -3.815M 27.94% | -3.101M 34.06% | -3.213M 32.98% |
All data in USD
8 analysts have analysed VIVE and the average price target is 4.77 USD. This implies a price increase of 2066.52% is expected in the next year compared to the current price of 0.2201.
VIVEVE MEDICAL INC (VIVE) will report earnings on 2023-03-15.
The consensus EPS estimate for the next earnings of VIVEVE MEDICAL INC (VIVE) is -0.63 USD and the consensus revenue estimate is 1.80M USD.
The number of analysts covering VIVEVE MEDICAL INC (VIVE) is 8.